UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2942-2962

2013

Volltextzugriff (PDF)

Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue

Cancer prevention research (Philadelphia, Pa.), 2021-01, Vol.14 (1), p.1-4

Vogel, Victor G

2021

Volltextzugriff (PDF)

Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2013-03, Vol.31 (7), p.961-965

2013

Volltextzugriff (PDF)

Breast cancer risk reduction: Notable achievements and remaining challenges

The breast journal, 2020-01, Vol.26 (1), p.86-91

Vogel, Victor G.

2020

Volltextzugriff (PDF)

Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction

Journal of clinical oncology, 2012-10, Vol.30 (30), p.3734-3745

2012

Volltextzugriff (PDF)

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Journal of clinical oncology, 2008-02, Vol.26 (5), p.778-785

2008

Volltextzugriff (PDF)

Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction

BMC medicine, 2015-03, Vol.13 (1), p.63-63, Article 63

Vogel, Victor G

2015

Volltextzugriff (PDF)

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2327-2333

2011

Volltextzugriff (PDF)

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

Expert review of anticancer therapy, 2009-01, Vol.9 (1), p.51-60

Vogel, Victor G

2009

Volltextzugriff (PDF)

The Burdens and Uncertainties of Doing What One Should Do

Cancer prevention research (Philadelphia, Pa.), 2017-08, Vol.10 (8), p.431-433

Vogel, Victor G

2017

Volltextzugriff (PDF)

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

The New England journal of medicine, 2010-06, Vol.362 (22), p.2053-2065

2010

Volltextzugriff (PDF)

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

Cancer prevention research (Philadelphia, Pa.), 2010-06, Vol.3 (6), p.696-706

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

Journal of clinical oncology, 2006-11, Vol.24 (31), p.5091-5097

2006

Volltextzugriff (PDF)

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7811-7819

2005

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3235-3258

2009

Volltextzugriff (PDF)

Preventive therapy for breast cancer: a consensus statement

The lancet oncology, 2011-05, Vol.12 (5), p.496-503

2011

Volltextzugriff (PDF)

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1965-1971

2008

Volltextzugriff (PDF)

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4160-4167

2011

Volltextzugriff (PDF)

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1673-1684

2005

Volltextzugriff (PDF)

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention

Current drug targets, 2011-12, Vol.12 (13), p.1874-1887

Vogel, Victor G

2011

Volltextzugriff (PDF)

Benzyl isothiocyanate–induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak

Molecular cancer therapeutics, 2006-11, Vol.5 (11), p.2931-2945

2006

Volltextzugriff (PDF)

Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer

Menopause (New York, N.Y.), 2008-07, Vol.15 (4 Suppl), p.782-789

Vogel, Victor G

2008

Volltextzugriff (PDF)

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

JAMA : the journal of the American Medical Association, 2006-06, Vol.295 (23), p.2727

2006

Volltextzugriff (PDF)

Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

JAMA network open, 2018-09, Vol.1 (5), p.e182140-e182140

2018

Volltextzugriff (PDF)

1 – 25 von 437

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(387)
Mit Volltextzugriff
(374)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(259)
Life Sciences & Biomedicine
(233)
Humans
(219)
Female
(171)
Oncology
(111)
Middle Aged
(96)
Biological And Medical Sciences
(81)
Medical Sciences
(81)
Adult
(78)
Aged
(66)
Breast Neoplasms - Prevention & Control
(61)
Risk Factors
(59)
Breast Cancer
(56)
Male
(52)
Tumors
(49)
Tamoxifen - Therapeutic Use
(40)
Animals
(34)
Gynecology. Andrology. Obstetrics
(33)
Mammary Gland Diseases
(33)
Breast Neoplasms - Epidemiology
(32)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(237)
EZB Electronic Journals Library
(228)
Journals@Ovid Full Text
(200)
Ingenta
(168)
NUS Single-Journal Subscriptions
(113)
IngentaConnect Journals
(94)
Access via ScienceDirect (Elsevier)
(60)
Wiley Online Library Journals
(56)
Wiley Online Library
(42)
SpringerLink
(42)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(34)
EZB-NALI5-00465 Elsevier Archive NL
(31)
Oxford Journals
(28)
Oxford Journals 2020 Medicine
(26)
JSTOR
(19)
Taylor & Francis Journals
(15)
Ebook Central Perpetual and DDA
(13)
eBooks on EBSCOhost
(12)
Taylor & Francis
(11)
Nature Journals Online
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue

Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

Breast cancer risk reduction: Notable achievements and remaining challenges

Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

The Burdens and Uncertainties of Doing What One Should Do

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Preventive therapy for breast cancer: a consensus statement

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention

Benzyl isothiocyanate–induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak

Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants

Suchergebnisse filtern